Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 6 (2009), Issue 9 (September)

1. Parstatin, a novel protease-activated receptor 1-derived inhibitor of angiogenesis.
   Mol Interv, 9(4): 168-70. [Abstract] [Full-text]
2. Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
   Eur J Cancer, 45(14): 2452-61. [Abstract] [Full-text]
3. Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy.
   J Clin Microbiol, 47(9): 2883-7. [Abstract] [Full-text]
4. Could local delivery of bisphosphonates be a new therapeutic choice for hemangiomas?
   Med Hypotheses, 73(4): 495-7. [Abstract] [Full-text]
5. Host-guest chemistry of dendrimer-drug complexes. 2. Effects of molecular properties of guests and surface functionalities of dendrimers.
   J Phys Chem B, 113(31): 10650-9. [Abstract] [Full-text]
6. Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer.
   Prostate Cancer Prostatic Dis, 12(3): 241-6. [Abstract] [Full-text]
7. Long-term outcome after polychemotherapy and intensive local radiation therapy of high-grade osteosarcoma.
   Eur J Cancer, 45(14): 2447-51. [Abstract] [Full-text]
8. Ultrasound assistant chemotherapy may be a novel modality for solid tumors.
   Med Hypotheses, 73(4): 526-7. [Abstract] [Full-text]
9. Is it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs.
   Med Hypotheses, 73(4): 606-7. [Abstract] [Full-text]
10. PDT combined with Intravesical BCG instillation would form an autovaccine for bladder cancer?
    Med Hypotheses, 73(4): 559-60. [Abstract] [Full-text]
11. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
    Eur J Cancer, 45(14): 2528-36. [Abstract] [Full-text]
12. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.
    Gastroenterology, 137(3): 1102-13. [Abstract] [Full-text]
13. Ocular haemodynamic changes after single treatment with photodynamic therapy assessed with non-invasive techniques.
    Acta Ophthalmol, 87(6): 631-7. [Abstract] [Full-text]
14. Multifunctional protein nanocarriers for targeted nuclear gene delivery in nondividing cells.
    FASEB J, 23(9): 2996-3006. [Abstract] [Full-text]
15. Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice.
    Crit Rev Oncol Hematol, 72(1): 10-20. [Abstract] [Full-text]
16. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.
    JAMA, 302(9): 962-8. [Abstract] [Full-text]
17. Management of acute ischemic stroke: current status of pharmacological and mechanical endovascular methods.
    Neurol Res, 31(8): 807-15. [Abstract] [Full-text]
18. Off-label prescribing: a call for heightened professional and government oversight.
    J Law Med Ethics, 37(3): 476-86, 396. [Abstract] [Full-text]
19. Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.
    Ann N Y Acad Sci, 1171: 627-34. [Abstract] [Full-text]
20. Magnetorelaxometric quantification of magnetic nanoparticles in an artery model after ex vivo magnetic drug targeting.
    Phys Med Biol, 54(18): N417-24. [Abstract] [Full-text]
21. Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles.
    J Am Chem Soc, 131(31): 11174-8. [Abstract] [Full-text]
22. Delivery of bioactive conjugated linoleic acid with self-assembled amylose-CLA complex.
    J Agric Food Chem, 57(15): 7125-30. [Abstract] [Full-text]
23. Photodynamic therapy for Acinetobacter baumannii burn infections in mice.
    Antimicrob Agents Chemother, 53(9): 3929-34. [Abstract] [Full-text]
24. Formation of naproxen-polylactic acid nanoparticles from supercritical solutions and their characterization in the aerosol phase.
    Phys Chem Chem Phys, 11(36): 7861-8. [Abstract] [Full-text]
25. Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain.
    J Neurosci, 29(35): 10961-73. [Abstract] [Full-text]
26. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
    N Engl J Med, 361(10): 947-57. [Abstract] [Full-text]
27. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
    Am J Hematol, 84(9): 553-9. [Abstract] [Full-text]
28. Exposure to both radiation and chemotherapy increases the risk of Barrett's and multilayered epithelium.
    Dig Dis Sci, 54(10): 2143-9. [Abstract] [Full-text]
29. Generation of gene knockout mice by ES cell microinjection.
    Curr Protoc Cell Biol. [Abstract] [Full-text]
30. Ambulatory arterial stiffness index in Turner syndrome: the impact of sex hormone replacement therapy.
    Horm Res, 72(3): 184-9. [Abstract] [Full-text]
31. Mediastinal Kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon in an infant: treatment with interferon.
    J Pediatr Hematol Oncol, 31(9): 690-2. [Abstract] [Full-text]
32. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.
    Blood, 114(10): 2051-9. [Abstract] [Full-text]
33. Hormone therapy and skeletal muscle strength: a meta-analysis.
    J Gerontol A Biol Sci Med Sci, 64(10): 1071-81. [Abstract] [Full-text]
34. Policies and institutional arrangements for rationalizing drug selection and consumption patterns in African healthcare systems.
    Res Social Adm Pharm, 5(3): 274-85. [Abstract] [Full-text]
35. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.
    Cancer Cell, 16(3): 259-66. [Abstract] [Full-text]
36. Optimal drug combinations and minimal hitting sets.
    BMC Syst Biol, 3: 81. [Abstract] [Full-text]
37. Nanosized polyamidoamine (PAMAM) dendrimer-induced apoptosis mediated by mitochondrial dysfunction.
    Toxicol Lett, 190(2): 202-7. [Abstract] [Full-text]
38. Synthesis of organoplatinum poly(dendrimer)s: pronounced effect of size and geometry of small organoplatinum linkers on the copolymerization efficiency with bifunctional dendritic macromonomers.
    Chemistry, 15(35): 8874-9. [Abstract] [Full-text]
39. Noncovalent synthesis of protein dendrimers.
    Chemistry, 15(35): 8760-7. [Abstract] [Full-text]
40. Antiretroviral therapy restores diversity in the T-cell receptor Vbeta repertoire of CD4 T-cell subpopulations among human immunodeficiency virus type 1-infected children and adolescents.
    Clin Vaccine Immunol, 16(9): 1293-301. [Abstract] [Full-text]
41. Fatty acid metabolism in the elderly: effects of dehydroepiandrosterone and testosterone replacement in hormonally deficient men and women.
    J Clin Endocrinol Metab, 94(9): 3414-23. [Abstract] [Full-text]
42. A novel gel based vehicle for the delivery of acetylcholine in quantitative sudomotor axon reflex testing.
    Auton Neurosci, 150(1): 127-30. [Abstract] [Full-text]
43. Characterization and anti-microbial susceptibility of gram-negative bacteria isolated from bloodstream infections of cancer patients on chemotherapy in Pakistan.
    Indian J Med Microbiol, 27(4): 341-7. [Abstract] [Full-text]
44. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus.
    Int J Radiat Oncol Biol Phys, 75(2): 348-56. [Abstract] [Full-text]
45. Radiotherapy and concomitant intra-arterial docetaxel combined with systemic 5-fluorouracil and cisplatin for oropharyngeal cancer: a preliminary report--improvement of locoregional control of oropharyngeal cancer.
    Int J Radiat Oncol Biol Phys, 75(2): 338-42. [Abstract] [Full-text]
46. Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide.
    Biochemistry, 48(36): 8624-35. [Abstract] [Full-text]
47. Reperfusion after stroke sonothrombolysis with microbubbles may predict intracranial bleeding.
    Neurology, 73(10): 775-80. [Abstract] [Full-text]
48. Prostate cancer: a newly discovered route for testosterone to reach the prostate : Treatment by super-selective intraprostatic androgen deprivation.
    Andrologia, 41(5): 305-15. [Abstract] [Full-text]
49. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants.
    Trends Pharmacol Sci, 30(9): 484-93. [Abstract] [Full-text]
50. Conciliating binding efficiency and polypharmacology.
    Trends Pharmacol Sci, 30(9): 470-4. [Abstract] [Full-text]
51. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).
    Br J Cancer, 101(6): 924-34. [Abstract] [Full-text]
52. Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma.
    J Vet Intern Med, 23(5): 1058-63. [Abstract] [Full-text]
53. Intraoperative photodynamic evaluation of surgical margins during endoscopic extraperitoneal radical prostatectomy with the use of 5-aminolevulinic acid.
    J Endourol, 23(9): 1387-94. [Abstract] [Full-text]
54. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.
    Br J Cancer, 101(6): 998-1004. [Abstract] [Full-text]
55. Adjuvant chemotherapy for breast cancer and cognitive impairment.
    South Med J, 102(9): 929-34. [Abstract] [Full-text]
56. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine.
    J Clin Oncol, 27(26): 4254-9. [Abstract] [Full-text]
57. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial.
    J Clin Oncol, 27(26): 4268-73. [Abstract] [Full-text]
58. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
    J Clin Oncol, 27(26): 4247-53. [Abstract] [Full-text]
59. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
    J Clin Oncol, 27(26): 4413-21. [Abstract] [Full-text]
60. Does sonographic needle guidance affect the clinical outcome of intraarticular injections?
    J Rheumatol, 36(9): 1892-902. [Abstract] [Full-text]
61. Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy.
    J Clin Oncol, 27(26): 4333-8. [Abstract] [Full-text]
62. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
    Oncology, 77(2): 113-9. [Abstract] [Full-text]
63. Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma.
    J Vet Intern Med, 23(5): 1064-70. [Abstract] [Full-text]
64. What is your diagnosis? Marked hyperchloremia in a dog.
    Vet Clin Pathol, 38(3): 411-4. [Abstract] [Full-text]
65. Proximal humerus intraosseous infusion: a preferred emergency venous access.
    J Trauma, 67(3): 606-11. [Abstract] [Full-text]
66. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy.
    Clin Infect Dis, 49(7): 1119-27. [Abstract] [Full-text]
67. Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials.
    Cancer, 115(18): 4210-7. [Abstract] [Full-text]
68. Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural population.
    Cancer, 115(18): 4167-75. [Abstract] [Full-text]
69. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.
    Cancer, 115(18): 4104-9. [Abstract] [Full-text]
70. A simulation for teaching the basic and clinical science of fluid therapy.
    Adv Physiol Educ, 33(3): 202-8. [Abstract] [Full-text]
71. Generic medicines: Greek physicians' perceptions and prescribing practices.
    J Clin Pharm Ther, 34(5): 547-54. [Abstract] [Full-text]
72. Total estrogen time and obstructive coronary disease in women: insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE).
    J Womens Health (Larchmt), 18(9): 1315-22. [Abstract] [Full-text]
73. Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib.
    PLoS Comput Biol, 5(9): e1000503. [Abstract] [Full-text]
74. Influence of the route of administration on immunomodulatory properties of bovine beta-lactoglobulin-producing Lactobacillus casei.
    Vaccine, 27(42): 5800-5. [Abstract] [Full-text]
75. Therapeutic options and patterns of prescription in chronic venous disorders: results of a 3-year survey in Italy.
    Eur J Vasc Endovasc Surg, 38(4): 511-7. [Abstract] [Full-text]
76. A genome-wide association study of acenocoumarol maintenance dosage.
    Hum Mol Genet, 18(19): 3758-68. [Abstract] [Full-text]
77. Microspheres as a vehicle for biomolecule delivery to neural stem cells.
    N Biotechnol, 25(6): 442-9. [Abstract] [Full-text]
78. Attitudes regarding mental health nurse prescribing among psychiatrists and nurses: a cross-sectional questionnaire study.
    Int J Nurs Stud, 46(11): 1467-74. [Abstract] [Full-text]
79. Novel antibody specificities targeting glycoprotein B of cytomegalovirus identified by molecular library technology.
    N Biotechnol, 25(6): 429-36. [Abstract] [Full-text]
80. A pilot study of dual-isotope lymphoscintigraphy for breast sentinel node biopsy comparing intradermal and intraparenchymal injection.
    Eur J Surg Oncol, 35(10): 1041-7. [Abstract] [Full-text]
81. Quantitative intra-operative assessment of peritoneal carcinomatosis - a comparison of three prognostic tools.
    Eur J Surg Oncol, 35(10): 1078-84. [Abstract] [Full-text]
82. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
    Eur J Surg Oncol, 35(10): 1048-54. [Abstract] [Full-text]
83. Embolic stroke associated with injection of buprenorphine tablets.
    Neurology, 73(11): 876-9. [Abstract] [Full-text]
84. Population-based intervention to reduce prehospital delays in patients with cerebrovascular events.
    Arch Intern Med, 169(16): 1484-90. [Abstract] [Full-text]
85. Alzheimer's disease drug development and the problem of the blood-brain barrier.
    Alzheimers Dement, 5(5): 427-32. [Abstract] [Full-text]
86. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry.
    Int J Antimicrob Agents, 34(5): 446-50. [Abstract] [Full-text]
87. Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infection.
    Int J Antimicrob Agents, 34(5): 471-3. [Abstract] [Full-text]
88. Efficacy of ciprofloxacin versus doxycycline as prophylaxis against experimental murine Brucella melitensis infection.
    Int J Antimicrob Agents, 34(5): 474-6. [Abstract] [Full-text]
89. Influence of antiretroviral therapy on programmed death-1 (CD279) expression on T cells in lymph nodes of human immunodeficiency virus-infected individuals.
    Hum Pathol, 40(10): 1427-33. [Abstract] [Full-text]
90. Microinjection techniques for studying mitosis in the Drosophila melanogaster syncytial embryo.
    J Vis Exp. [Abstract] [Full-text]
91. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer.
    Cancer Res, 69(18): 7466-72. [Abstract] [Full-text]
92. Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors.
    J Transl Med, 7: 77. [Abstract] [Full-text]
93. Influence of melanosome dynamics on melanoma drug sensitivity.
    J Natl Cancer Inst, 101(18): 1259-71. [Abstract] [Full-text]
94. Intracellular delivery of bovine lactoferricin's antimicrobial core (RRWQWR) kills T-leukemia cells.
    Biochem Biophys Res Commun, 388(4): 736-41. [Abstract] [Full-text]
95. Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways.
    Biochem Biophys Res Commun, 388(4): 705-10. [Abstract] [Full-text]
96. Improved quality in the hospital discharge summary reduces medication errors--LIMM: Landskrona Integrated Medicines Management.
    Eur J Clin Pharmacol, 65(10): 1037-46. [Abstract] [Full-text]
97. Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: a report of the Italian Association of Pediatric Hematology and Oncology.
    Pediatr Blood Cancer, 53(6): 953-9. [Abstract] [Full-text]
98. Varied opinions on thrombolysis for venous thromboembolism in infants and children: findings from a survey of pediatric hematology-oncology specialists.
    Pediatr Blood Cancer, 53(6): 960-6. [Abstract] [Full-text]
99. Medical monitoring in patients with bipolar disorder: clinical recommendations.
    J Clin Psychiatry, 70(8): e27. [Abstract] [Full-text]
100. The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer.
     Cancer Chemother Pharmacol, 65(1): 191-5. [Abstract] [Full-text]
101. Cisplatin-based chemotherapy for advanced seminoma: report of 52 cases treated in two institutions.
     J Cancer Res Clin Oncol, 135(11): 1495-500. [Abstract] [Full-text]
102. Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?
     Ann Hematol, 88(11): 1107-12. [Abstract] [Full-text]
103. The difficult venous ulcer: case series of 177 ulcers referred for vascular surgical opinion following failure of conservative management.
     Angiology, 60(4): 492-5. [Abstract] [Full-text]
104. Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea.
     Ann Hematol, 88(11): 1099-106. [Abstract] [Full-text]
105. Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.
     Ann Hematol, 88(11): 1069-77. [Abstract] [Full-text]
106. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.
     Ann Hematol, 88(11): 1125-30. [Abstract] [Full-text]
107. Use of alternative medicines by patients with OA that adversely interact with commonly prescribed medications.
     Clin Orthop Relat Res, 467(10): 2705-22. [Abstract] [Full-text]
108. A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma.
     Cancer Chemother Pharmacol, 65(1): 151-7. [Abstract] [Full-text]
109. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
     Cancer Chemother Pharmacol, 65(1): 167-75. [Abstract] [Full-text]
110. Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors.
     Cancer Chemother Pharmacol, 65(1): 137-42. [Abstract] [Full-text]
111. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
     Cancer Chemother Pharmacol, 65(1): 97-105. [Abstract] [Full-text]
112. A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors.
     Cancer Chemother Pharmacol, 65(1): 121-8. [Abstract] [Full-text]
113. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
     Cancer Chemother Pharmacol, 65(1): 113-20. [Abstract] [Full-text]
114. A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors.
     Cancer Chemother Pharmacol, 65(1): 33-40. [Abstract] [Full-text]
115. Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines.
     Cancer Chemother Pharmacol, 65(1): 5-12. [Abstract] [Full-text]
116. Thrombolysis targeting MRI defined tissue at risk in minor stroke.
     J Neurol Neurosurg Psychiatry, 80(10): 1156-8. [Abstract] [Full-text]
117. The effect of obesity on neuraxial technique difficulty in pregnant patients: a prospective, observational study.
     Anesth Analg, 109(4): 1225-31. [Abstract] [Full-text]
118. An analysis of drug delivery dynamics via a pediatric central venous infusion system: quantification of delays in achieving intended doses.
     Anesth Analg, 109(4): 1156-61. [Abstract] [Full-text]
119. Impact of multiaccess infusion devices on in vitro drug delivery during multi-infusion therapy.
     Anesth Analg, 109(4): 1147-55. [Abstract] [Full-text]
120. No evidence for variation in colorectal cancer risk associated with different types of postmenopausal hormone therapy.
     Clin Pharmacol Ther, 86(4): 416-24. [Abstract] [Full-text]
121. Postexercise rehydration in man: the effects of carbohydrate content and osmolality of drinks ingested ad libitum.
     Appl Physiol Nutr Metab, 34(4): 785-93. [Abstract] [Full-text]
122. Using National Drug Codes and drug knowledge bases to organize prescription records from multiple sources.
     Am J Health Syst Pharm, 66(19): 1743-53. [Abstract] [Full-text]
123. Targeting NF-kappa B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis.
     J Immunol, 183(7): 4755-63. [Abstract] [Full-text]
124. Therapeutic efficacy of Bifidobacterium longum-mediated human granulocyte colony-stimulating factor and/or endostatin combined with cyclophosphamide in mouse-transplanted tumors.
     Cancer Sci, 100(10): 1986-90. [Abstract] [Full-text]
125. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
     Cancer Sci, 100(10): 1842-7. [Abstract] [Full-text]
126. The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy.
     Eur J Endocrinol, 161(4): 541-6. [Abstract] [Full-text]
127. Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer.
     Cancer Sci, 100(10): 1979-85. [Abstract] [Full-text]
128. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.
     Cancer Sci, 100(10): 1951-6. [Abstract] [Full-text]
129. MRI-guided injection procedures of the temporomandibular joints in children and adults: technique, accuracy, and safety.
     AJR Am J Roentgenol, 193(4): 1148-54. [Abstract] [Full-text]
130. Digital subtraction angiography-guided percutaneous transcatheter foam sclerotherapy of varicocele: a novel tracking technique.
     AJR Am J Roentgenol, 193(4): 978-80. [Abstract] [Full-text]
131. Modifying peripheral IV catheters with side holes and side slits results in favorable changes in fluid dynamic properties during the injection of iodinated contrast material.
     AJR Am J Roentgenol, 193(4): 970-7. [Abstract] [Full-text]
132. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols.
     AJR Am J Roentgenol, 193(4): 941-7. [Abstract] [Full-text]
133. Epidural steroid injection resulting in epidural hematoma in a patient despite strict adherence to anticoagulation guidelines.
     J Neurosurg Spine, 11(3): 358-64. [Abstract] [Full-text]
134. Cerebral venous sinus thrombosis: a case series including thrombolysis.
     Arch Dis Child, 94(10): 790-4. [Abstract] [Full-text]
135. Photodynamic treatment of culture medium containing serum induces long-lasting toxicity in vitro.
     Radiat Res, 172(4): 451-62. [Abstract] [Full-text]
136. Intravitreal triamcinolone acetonide preceding photodynamic therapy for exudative age-related macular degeneration.
     Ophthalmic Surg Lasers Imaging, 40(5): 467-71. [Abstract] [Full-text]
137. Prevention of Plasmodium vivax malaria recurrence: efficacy of the standard total dose of primaquine administered over 3 days.
     Acta Trop, 112(2): 188-92. [Abstract] [Full-text]
138. Anthracycline dose intensification in acute myeloid leukemia.
     N Engl J Med, 361(13): 1249-59. [Abstract] [Full-text]
139. High-dose daunorubicin in older patients with acute myeloid leukemia.
     N Engl J Med, 361(13): 1235-48. [Abstract] [Full-text]
140. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
     Oncology, 77(3): 224-30. [Abstract] [Full-text]
141. Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.
     Oncology, 77(3): 212-6. [Abstract] [Full-text]
142. Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
     Oncology, 77(3): 192-6. [Abstract] [Full-text]
143. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases.
     Exp Biol Med (Maywood), 234(10): 1244-52. [Abstract] [Full-text]
144. Engineering nanomaterial surfaces for biomedical applications.
     Exp Biol Med (Maywood), 234(10): 1128-39. [Abstract] [Full-text]
145. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries.
     Lancet Infect Dis, 9(10): 637-49. [Abstract] [Full-text]
146. Topical chlormethine hydrochloride causing bullous reaction.
     Clin Toxicol (Phila), 47(8): 834-5. [Abstract] [Full-text]
147. Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.
     Blood, 114(13): 2678-87. [Abstract] [Full-text]
148. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
     Blood, 114(13): 2733-43. [Abstract] [Full-text]
149. Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.
     Cancer Immunol Immunother, 58(12): 2031-7. [Abstract] [Full-text]
150. One-day application of topical moxifloxacin 0.5% to select for fluoroquinolone-resistant coagulase-negative Staphylococcus.
     J Cataract Refract Surg, 35(10): 1715-8. [Abstract] [Full-text]
151. Prophylactic effect of clarithromycin in skin flap complications in cochlear implants surgery.
     Laryngoscope, 119(10): 2032-6. [Abstract] [Full-text]
152. Indicators for the correct usage of intranasal medications: A computational fluid dynamics study.
     Laryngoscope, 119(10): 1975-82. [Abstract] [Full-text]
153. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial.
     Am J Kidney Dis, 54(4): 610-8. [Abstract] [Full-text]
154. Effect of slow-releasing all-trans-retinoic acid in bioabsorbable polymer on delayed adjustable strabismus surgery in a rabbit model.
     Am J Ophthalmol, 148(4): 566-72. [Abstract] [Full-text]
155. Risk factors for peripheral intravenous catheter infection in hospitalized patients: a prospective study of 3165 patients.
     Am J Infect Control, 37(8): 683-6. [Abstract] [Full-text]
156. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231.
     Cancer Lett, 285(1): 28-38. [Abstract] [Full-text]
157. Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment.
     Cancer Lett, 285(1): 58-65. [Abstract] [Full-text]
158. An analysis of the association between parental acculturation and children's medication use.
     Pediatrics, 124(4): 1152-61. [Abstract] [Full-text]
159. Side effects of phytoestrogens: a meta-analysis of randomized trials.
     Am J Med, 122(10): 939-46.e9. [Abstract] [Full-text]
160. Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy.
     BMC Infect Dis, 9: 140. [Abstract] [Full-text]
161. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial.
     Br J Cancer, 101(7): 1033-8. [Abstract] [Full-text]
162. Thyroid hormone replacement after thyroid lobectomy.
     Surgery, 146(4): 554-8; discussion 558-60. [Abstract] [Full-text]
163. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
     Br J Cancer, 101(7): 1044-50. [Abstract] [Full-text]
164. Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer.
     Br J Cancer, 101(7): 1059-65. [Abstract] [Full-text]
165. Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
     Br J Cancer, 101(7): 1039-43. [Abstract] [Full-text]
166. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.
     Br J Cancer, 101(7): 1162-7. [Abstract] [Full-text]
167. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
     J Clin Oncol, 27(28): 4733-40. [Abstract] [Full-text]
168. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.
     J Clin Oncol, 27(28): 4693-700. [Abstract] [Full-text]
169. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024.
     J Clin Oncol, 27(28): 4727-32. [Abstract] [Full-text]
170. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
     J Clin Oncol, 27(28): 4649-55. [Abstract] [Full-text]
171. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
     J Clin Oncol, 27(28): 4787-92. [Abstract] [Full-text]
172. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
     J Clin Oncol, 27(28): 4741-6. [Abstract] [Full-text]
173. Interactions between octaarginine and U-937 human macrophages: global gene expression profiling, superoxide anion content, and cytokine production.
     J Control Release, 139(3): 197-204. [Abstract] [Full-text]
174. Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization.
     J Control Release, 139(3): 239-45. [Abstract] [Full-text]
175. Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.
     J Control Release, 139(3): 190-6. [Abstract] [Full-text]
176. A flexible drug delivery chip for the magnetically-controlled release of anti-epileptic drugs.
     J Control Release, 139(3): 221-8. [Abstract] [Full-text]
177. L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL).
     J Control Release, 139(3): 182-9. [Abstract] [Full-text]
178. Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin.
     J Control Release, 139(3): 212-20. [Abstract] [Full-text]
179. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells.
     J Control Release, 139(3): 174-81. [Abstract] [Full-text]
180. A biodegradable filament for controlled drug delivery.
     J Control Release, 139(3): 205-11. [Abstract] [Full-text]
181. Combined treatment of human MCF-7 breast carcinoma with antibody, cationic lipid and hyaluronic acid using ex vivo assays.
     J Pharm Biomed Anal, 51(1): 192-201. [Abstract] [Full-text]
182. Correlation between the free volume and the metoprolol tartrate release of Metolose patches.
     J Pharm Biomed Anal, 51(1): 244-7. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.